Unknown

Dataset Information

0

Finding the clinical utility of 1,5-anhydroglucitol among primary care practitioners.


ABSTRACT:

Background

HbA1c is widely used as the standard measure to track glycemic control in patients with diabetes and pre-diabetes but measures average levels of glycated hemoglobin over two to three months, with limited utility in the presence of recent and/or short-term fluctuations in glycemic control, which are correlated with worse patient outcomes.

Methods

We examined the clinical utility of 1-5-anhydroglucitol (1,5-AG) in six different, but common, case types of diabetes patients with short-term glycemic variability. We conducted a randomized controlled trial of simulated patients to examine the clinical practice patterns of primary care physicians before and after introducing 1,5-AG. The 145 participants were randomly assigned into standard care or standard care + 1,5-AG arms. Provider care was reviewed against explicit evidence-based care standards.

Results

At baseline, we saw no difference between the two study arms in clinical quality of care provided (p = 0.997). After introduction of 1,5-AG, standard care + 1,5-AG providers performed 3.2% better than controls (p = 0.025. In diagnosis and treatment, there was a slight, but nonsignificant trend toward better care (+1.1%, p = 0.507) for intervention providers. Upon disaggregation by case, almost all the improvement occurred in the medication-induced hyperglycemia patients (+8.1%, p = 0.047).

Conclusions

A nationally representative sample of primary care physicians demonstrated that of six different cases used in this study, 1,5-AG was found to be most effective increasing awareness of poor glucose control in medication-induced hyperglycemia. If 1,5-AG is used in this particular circumstance, the overall savings to the healthcare system is estimated to be $28 million.

SUBMITTER: Peabody J 

PROVIDER: S-EPMC7184171 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Finding the clinical utility of 1,5-anhydroglucitol among primary care practitioners.

Peabody John J   Paculdo David D   Acelajado M Czarina MC   Burgon Trever T   Dahlen Jeffrey R JR  

Journal of clinical & translational endocrinology 20200418


<h4>Background</h4>HbA1c is widely used as the standard measure to track glycemic control in patients with diabetes and pre-diabetes but measures average levels of glycated hemoglobin over two to three months, with limited utility in the presence of recent and/or short-term fluctuations in glycemic control, which are correlated with worse patient outcomes.<h4>Methods</h4>We examined the clinical utility of 1-5-anhydroglucitol (1,5-AG) in six different, but common, case types of diabetes patients  ...[more]

Similar Datasets

2023-01-03 | GSE221889 | GEO
| S-EPMC6129696 | biostudies-literature
| S-EPMC4215646 | biostudies-literature
| S-EPMC8369766 | biostudies-literature
| S-EPMC6262337 | biostudies-literature
| S-EPMC5924648 | biostudies-literature
| S-EPMC5860021 | biostudies-literature
| S-EPMC9277777 | biostudies-literature
| S-EPMC7648735 | biostudies-literature
| S-EPMC7344450 | biostudies-literature